Multidisciplinary Treatment of Early Stage Endometrial Cancer

Author(s): S. C. Cecere, C. Pisano, A. Bamias, M. Di Napoli, S. Rossetti, G. Facchini, R. Tambaro, S. Pignata

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 13 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


Endometrial cancer is a highly curable malignancy when it presents as uterine-confined disease, but the prognosis for metastatic or recurrent endometrial cancer is poor. For those patients which are diagnosed at an early stage, surgery alone may be adequate for cure and clinical outcome is often favorable, with approximately 80 % of cases surviving at 5 years. However, after primary diagnosis and treatment, roughly 20-30% of patients are expected to recur within the following 5 years. Adjuvant treatment for endometrial cancer is not yet clearly defined. FIGO Stage I-III endometrial cancer patients, usually undergo surgery and some of them are offered adjuvant treatment based on risk assessment. Grade, age, stage are considered all independent risk factors for recurrence. Radiotherapy (RT) has been considered the adjuvant treatment of choice for decades, being able to reduce local recurrence rate and improving progression free survival, but without any impact on overall survival. In the last two decades, a shift toward the use of systemic chemotherapy (CT) in addition or instead of radiation has occurred, although few prospective studies have been performed in this field.

Keywords: Adjuvant chemotherapy, hormonal therapy, endometrial cancer, prognostic factors, radiation therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 May, 2013
Page: [861 - 871]
Pages: 11
DOI: 10.2174/18715206113139990111
Price: $65

Article Metrics

PDF: 21